Cargando…
Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET tracer [(18)F]THK5317 (also known as (S)-[(18)F]THK5117) retention in different stages of Alzheimer’s disease; and study any associations with markers of hypometabolism and amyloid-beta deposition. METHOD...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932128/ https://www.ncbi.nlm.nih.gov/pubmed/26996778 http://dx.doi.org/10.1007/s00259-016-3363-z |
_version_ | 1782441013966536704 |
---|---|
author | Chiotis, Konstantinos Saint-Aubert, Laure Savitcheva, Irina Jelic, Vesna Andersen, Pia Jonasson, My Eriksson, Jonas Lubberink, Mark Almkvist, Ove Wall, Anders Antoni, Gunnar Nordberg, Agneta |
author_facet | Chiotis, Konstantinos Saint-Aubert, Laure Savitcheva, Irina Jelic, Vesna Andersen, Pia Jonasson, My Eriksson, Jonas Lubberink, Mark Almkvist, Ove Wall, Anders Antoni, Gunnar Nordberg, Agneta |
author_sort | Chiotis, Konstantinos |
collection | PubMed |
description | PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET tracer [(18)F]THK5317 (also known as (S)-[(18)F]THK5117) retention in different stages of Alzheimer’s disease; and study any associations with markers of hypometabolism and amyloid-beta deposition. METHODS: Thirty-three individuals were enrolled, including nine patients with Alzheimer’s disease dementia, thirteen with mild cognitive impairment (MCI), two with non-Alzheimer’s disease dementia, and nine healthy controls (five young and four elderly). In a multi-tracer PET design [(18)F]THK5317, [(11)C] Pittsburgh compound B ([(11)C]PIB), and [(18)F]FDG were used to assess tau pathology, amyloid-beta deposition and cerebral glucose metabolism, respectively. The MCI patients were further divided into MCI [(11)C]PIB-positive (n = 11) and MCI [(11)C]PIB-negative (n = 2) groups. RESULTS: Test-retest variability for [(18)F]THK5317-PET was very low (1.17–3.81 %), as shown by retesting five patients. The patients with prodromal (MCI [(11)C]PIB-positive) and dementia-stage Alzheimer’s disease had significantly higher [(18)F]THK5317 retention than healthy controls (p = 0.002 and p = 0.001, respectively) in areas exceeding limbic regions, and their discrimination from this control group (using the area under the curve) was >98 %. Focal negative correlations between [(18)F]THK5317 retention and [(18)F]FDG uptake were observed mainly in the frontal cortex, and focal positive correlations were found between [(18)F]THK5317 and [(11)C]PIB retentions isocortically. One patient with corticobasal degeneration syndrome and one with progressive supranuclear palsy showed no [(11)C]PIB but high [(18)F]THK5317 retentions with a different regional distribution from that in Alzheimer’s disease patients. CONCLUSIONS: The tau-specific PET tracer [(18)F]THK5317 images in vivo the expected regional distribution of tau pathology. This distribution contrasts with the different patterns of hypometabolism and amyloid-beta deposition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-016-3363-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4932128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-49321282016-07-18 Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm Chiotis, Konstantinos Saint-Aubert, Laure Savitcheva, Irina Jelic, Vesna Andersen, Pia Jonasson, My Eriksson, Jonas Lubberink, Mark Almkvist, Ove Wall, Anders Antoni, Gunnar Nordberg, Agneta Eur J Nucl Med Mol Imaging Original Article PURPOSE: The aim of this study was to explore the cerebral distribution of the tau-specific PET tracer [(18)F]THK5317 (also known as (S)-[(18)F]THK5117) retention in different stages of Alzheimer’s disease; and study any associations with markers of hypometabolism and amyloid-beta deposition. METHODS: Thirty-three individuals were enrolled, including nine patients with Alzheimer’s disease dementia, thirteen with mild cognitive impairment (MCI), two with non-Alzheimer’s disease dementia, and nine healthy controls (five young and four elderly). In a multi-tracer PET design [(18)F]THK5317, [(11)C] Pittsburgh compound B ([(11)C]PIB), and [(18)F]FDG were used to assess tau pathology, amyloid-beta deposition and cerebral glucose metabolism, respectively. The MCI patients were further divided into MCI [(11)C]PIB-positive (n = 11) and MCI [(11)C]PIB-negative (n = 2) groups. RESULTS: Test-retest variability for [(18)F]THK5317-PET was very low (1.17–3.81 %), as shown by retesting five patients. The patients with prodromal (MCI [(11)C]PIB-positive) and dementia-stage Alzheimer’s disease had significantly higher [(18)F]THK5317 retention than healthy controls (p = 0.002 and p = 0.001, respectively) in areas exceeding limbic regions, and their discrimination from this control group (using the area under the curve) was >98 %. Focal negative correlations between [(18)F]THK5317 retention and [(18)F]FDG uptake were observed mainly in the frontal cortex, and focal positive correlations were found between [(18)F]THK5317 and [(11)C]PIB retentions isocortically. One patient with corticobasal degeneration syndrome and one with progressive supranuclear palsy showed no [(11)C]PIB but high [(18)F]THK5317 retentions with a different regional distribution from that in Alzheimer’s disease patients. CONCLUSIONS: The tau-specific PET tracer [(18)F]THK5317 images in vivo the expected regional distribution of tau pathology. This distribution contrasts with the different patterns of hypometabolism and amyloid-beta deposition. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00259-016-3363-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-03-21 2016 /pmc/articles/PMC4932128/ /pubmed/26996778 http://dx.doi.org/10.1007/s00259-016-3363-z Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Chiotis, Konstantinos Saint-Aubert, Laure Savitcheva, Irina Jelic, Vesna Andersen, Pia Jonasson, My Eriksson, Jonas Lubberink, Mark Almkvist, Ove Wall, Anders Antoni, Gunnar Nordberg, Agneta Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm |
title | Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm |
title_full | Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm |
title_fullStr | Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm |
title_full_unstemmed | Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm |
title_short | Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm |
title_sort | imaging in-vivo tau pathology in alzheimer’s disease with thk5317 pet in a multimodal paradigm |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932128/ https://www.ncbi.nlm.nih.gov/pubmed/26996778 http://dx.doi.org/10.1007/s00259-016-3363-z |
work_keys_str_mv | AT chiotiskonstantinos imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT saintaubertlaure imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT savitchevairina imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT jelicvesna imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT andersenpia imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT jonassonmy imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT erikssonjonas imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT lubberinkmark imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT almkvistove imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT wallanders imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT antonigunnar imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm AT nordbergagneta imaginginvivotaupathologyinalzheimersdiseasewiththk5317petinamultimodalparadigm |